Mysuru-based startup NuSynth Technologies has raised ₹36.5 crore in a seed round co-led by Avaana Capital and Shastra VC. The company leverages AI to redesign chemical synthesis routes, aiming to improve efficiency and reduce dependence on imported intermediates for the pharmaceutical and electronic chemical sectors. While this funding supports technology scaling, investors may note the execution challenges inherent in commercializing advanced chemical manufacturing.
NuSynth Technologies, a startup based in Mysuru, has successfully raised ₹36.5 crore in a seed funding round. The investment was co-led by venture capital firms Avaana Capital and Shastra VC, with participation from several angel investors. The company plans to use these funds to expand its research and development infrastructure, advance its proprietary technology stack, and recruit specialized talent to support its growth in the chemical manufacturing space.
Advancing Chemical Process Efficiency
The company’s core business model focuses on using artificial intelligence to redesign traditional chemical synthesis routes. Many current manufacturing processes in India rely on inefficient, multi-step pathways that increase energy consumption and cost. By using predictive models to optimize reaction pathways, NuSynth aims to replace these outdated methods with proprietary, streamlined designs. This approach is intended to lower production costs and improve safety and sustainability standards.
By targeting high-value verticals such as pharmaceutical ingredients and electronic chemicals, the startup is attempting to address a significant gap in the domestic manufacturing chain. The goal is to reduce the Indian industry's heavy reliance on imported chemical intermediates, potentially creating a more resilient supply chain for domestic manufacturers.
Leadership and Scaling Challenges
The leadership team includes CEO Poorvank Purohit, who previously led Solara Active Pharma Sciences, and CTO Dr. Ramesha A R, who brings experience from the National Institutes of Health. Their combined background in scientific research and commercial operations is intended to bridge the gap between lab-scale innovation and industrial-scale production. The company is also drawing on expertise from professionals with experience at operational-heavy organizations like Zetwerk and Ola.
Despite the potential for innovation, investors and industry observers often monitor several risks when evaluating early-stage chemical technology startups. The chemical sector is notoriously capital-intensive, and moving new technology from a laboratory setting to a commercial production scale involves significant execution risks. The success of the company will depend on whether its AI-driven synthesis routes can prove reliable and cost-effective under real-world manufacturing conditions. Furthermore, as an early-stage entity, the company will likely need to navigate competitive pressures from established chemical manufacturers and potential regulatory hurdles in the pharmaceutical and electronic chemical sectors. Future monitorables will include the company's ability to successfully commission its R&D projects and demonstrate the scalability of its synthesis technology in a commercial environment.